<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <title>Daily CSR</title>
 <subtitle><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></subtitle>
 <link rel="alternate" type="text/html" href="https://www.dailycsr.com" />
 <link rel="self" type="text/xml" href="https://www.dailycsr.com/xml/atom.xml" />
 <id>https://www.dailycsr.com/</id>
 <updated>2026-10-03T06:58:52+02:00</updated>
 <generator uri="http://www.wmaker.net">Webzine Maker</generator>
  <icon>https://www.dailycsr.com/favicon.ico</icon>
  <entry>
   <title>Leo Cancer Care Expands Pediatric Proton Therapy Program</title>
   <updated>2026-09-28T12:18:00+02:00</updated>
   <id>https://www.dailycsr.com/Leo-Cancer-Care-Expands-Pediatric-Proton-Therapy-Program_a6171.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/98180957-68378557.jpg</photo:imgsrc>
   <published>2026-09-28T12:16:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/98180957-68378557.jpg?v=1790590689" alt="Leo Cancer Care Expands Pediatric Proton Therapy Program" title="Leo Cancer Care Expands Pediatric Proton Therapy Program" />
     </div>
     <div>
      <div style="text-align: justify;">Leo Cancer Care is taking further steps to improve the treatment experience for children receiving radiation therapy. After supporting the world's first pediatric treatments using its Marie® upright positioning and imaging platform, the company has announced a dedicated pediatric program combining education, distraction techniques and gamification to create a more child-friendly treatment environment. <br />   <br />  <strong>First pediatric treatments completed</strong> <br />  In June 2026, Stanford Medicine performed the first treatments using the Mevion S250-FIT Proton Therapy System™, which incorporates Leo Cancer Care's Marie® upright positioning and imaging technology alongside RaySearch Laboratories' RayStation® treatment-planning system. <br />   <br />  The initial treatments demonstrated that proton therapy in an upright position can be successfully delivered to pediatric patients across a broad range of ages. The approach also preserves the option of using anesthesia when clinicians determine that it is appropriate for an individual child. <br />   <br />  <strong>Rethinking the position of pediatric patients</strong> <br />  Leo Cancer Care's approach is based on rethinking the conventional configuration of radiation therapy. Traditional systems generally move the radiation beam around a patient lying on a treatment table. With the company's upright concept, the beam remains stationary while the patient, positioned in a seated or semi-standing posture, is rotated into the required treatment positions. <br />   <br />  The upright setup may also allow children to become more engaged with the treatment process. Being seated or standing can give young patients a greater sense of participation and control, potentially helping to make an unfamiliar and intimidating procedure less stressful. <br />   <br />  <strong>Turning treatment into an experience children can understand</strong> <br />  The concept behind Leo Cancer Care's pediatric program is rooted in the idea that the treatment chair can become something imaginative in a child's mind—a spacecraft ready for launch or the cockpit of a racing car. <br />   <br />  That philosophy has been incorporated into a broader pediatric experience designed to prepare and engage young patients. An augmented-reality educational platform allows children to explore the upright treatment environment using a smartphone or tablet before their first appointment. The experience is guided by Leo the Lion, a character that also appears as a soft toy introduced during the child's initial oncology visit. <br />   <br />  The character features again in <em>Toby's Magic Chair</em>, a children's storybook that follows a young patient through the experience of receiving upright radiation therapy. <br />   <br />  Leo Cancer Care has also licensed AVATAR, a system developed at Stanford Medicine. The technology uses a radiolucent display positioned within the child's field of view during treatment, providing an immersive form of distraction that may help reduce anxiety and, in some cases, decrease reliance on anesthesia. <br />   <br />  <strong>New research and clinical guidance</strong> <br />  A new paper titled <em>Upright positioning in pediatric radiotherapy: rationale, safety considerations and a research roadmap</em> has been published in Technical Innovations &amp; Patient Support in Radiation Oncology. <br />   <br />  The publication was produced by the Upright Radiotherapy Pediatric Task Group, an international multidisciplinary group representing radiation oncology, medical physics, radiation therapy, pediatric anesthesia and industry, including Leo Cancer Care. <br />   <br />  According to the report, upright treatment positioning could help reduce distress among appropriately selected pediatric patients. However, the authors also emphasize that evidence specifically relating to children remains limited. The paper proposes a research agenda for evaluating upright radiotherapy in pediatric oncology and stresses the need for consistent, safety-focused clinical procedures. <br />   <br />  <strong>Moving toward a more patient-centered approach</strong> <br />  Children represent an important clinical population for proton therapy, yet patients who may benefit substantially from the technology have historically faced limitations in accessing it. <br />   <br />  Leo Cancer Care's approach is intended to make radiation treatment adapt more closely to the needs of the patient rather than requiring the patient to adapt to conventional treatment arrangements. Its upright platform is designed to support access to proton therapy while also changing the physical and emotional experience children encounter during treatment. <br />   <br />  The company says its broader objective is to make radiation therapy more human-centered by combining technological innovation with approaches that help young patients understand, participate in and feel more comfortable with their treatment. <br />   <br />  Leo Cancer Care is presenting its latest clinical developments and its longer-term vision at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting in Boston, where the company is exhibiting at booth 519.</div>  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Leo-Cancer-Care-Expands-Pediatric-Proton-Therapy-Program_a6171.html" />
  </entry>
  <entry>
   <title>Accuray and Samsung Explore Volumetric Imaging for CyberKnife</title>
   <updated>2026-09-28T11:49:00+02:00</updated>
   <id>https://www.dailycsr.com/Accuray-and-Samsung-Explore-Volumetric-Imaging-for-CyberKnife_a6163.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/98180657-68378102.jpg</photo:imgsrc>
   <published>2026-09-28T11:47:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/98180657-68378102.jpg?v=1790588973" alt="Accuray and Samsung Explore Volumetric Imaging for CyberKnife" title="Accuray and Samsung Explore Volumetric Imaging for CyberKnife" />
     </div>
     <div>
      <p style="text-align: justify;">Accuray Incorporated has entered into agreements with Samsung HME America, Inc., doing business as NeuroLogica Corp. (“Samsung NeuroLogica”), to explore advanced volumetric imaging capabilities for the CyberKnife&nbsp;System. The announcement was made in conjunction with the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, where the two companies are presenting their collaboration. The initiative forms part of Accuray’s broader approach of working with strategic partners to combine complementary technologies in response to customer needs.<o:p></o:p> <br />    <p style="text-align: justify;">According to Accuray, customers have identified imaging technologies that can support treatment efficiency and clinical decision-making as important priorities. The collaboration brings together Samsung NeuroLogica’s expertise in mobile computed tomography (CT) and volumetric imaging with Accuray’s capabilities in precision radiation delivery, robotic radiosurgery and real-time motion management.<o:p></o:p> <br />    <p style="text-align: justify;">Accuray President and CEO Steve La Neve said the partnership reflects the company’s focus on delivering relevant innovation more quickly while determining which capabilities should be developed internally and which can be advanced through collaboration. He said combining the two companies’ areas of expertise could help address clinical and patient needs identified by healthcare professionals.<o:p></o:p> <br />    <p style="text-align: justify;">Clinicians have told Accuray that volumetric imaging could provide a more comprehensive view of patient anatomy within the treatment environment and potentially support future treatment workflows. The companies are therefore examining ways to bring additional anatomical information closer to treatment-related decisions while maintaining the regulatory standards applicable to radiation oncology.<o:p></o:p> <br />    <p style="text-align: justify;">Professor Nicholas van As, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust and Chief Investigator of the PACE trials, said volumetric imaging could complement CyberKnife’s non-coplanar treatment delivery and real-time motion-management capabilities. According to van As, simultaneously viewing the treatment target and surrounding anatomy could provide clinicians with additional information during treatment. In the longer term, he said, the technology could potentially contribute to treatment approaches that account for changes in a patient’s anatomy on the day of treatment.<o:p></o:p> <br />    <p style="text-align: justify;">The Royal Marsden is the first center worldwide to participate in the Accuray–Samsung NeuroLogica collaboration. The center will help explore the potential contribution of Samsung’s volumetric imaging technology to robotic radiosurgery.<o:p></o:p> <br />    <p style="text-align: justify;">The potential application of volumetric imaging also extends beyond a single cancer type. Jonathan Lischalk, MD, Clinical Director of Radiosurgery at MedStar Georgetown University Hospital and Clinical Associate Professor at Georgetown University School of Medicine, said the technology could be relevant to thoracic, abdominal and pelvic cancers.<o:p></o:p> <br />    <p style="text-align: justify;">For clinicians treating cancers such as lung, pancreatic and prostate cancer, Lischalk noted that understanding the position of the treatment target relative to surrounding healthy organs can be important during treatment. He said evaluating additional imaging alongside CyberKnife’s non-coplanar delivery and real-time motion management could provide opportunities to investigate future approaches for dealing with changing patient anatomy.<o:p></o:p> <br />    <p style="text-align: justify;">The clinical perspectives supporting the collaboration reflect a broader interest in providing clinicians with more information at the point of treatment. Samsung NeuroLogica’s Boris Geyzer, Head of Business for Mobile CT at Samsung HME America, said the company’s work in mobile CT has focused on bringing advanced imaging closer to patients.<o:p></o:p> <br />    <p style="text-align: justify;">Geyzer described the collaboration as an effort to address a practical clinical requirement: improving visualization of anatomy within the treatment room. Samsung NeuroLogica contributes its experience in mobile CT and volumetric imaging, while Accuray brings expertise in precision radiation delivery and established knowledge of radiotherapy workflows. The companies are exploring how these capabilities could potentially be combined to address treatment-room needs.<o:p></o:p> <br />    <p style="text-align: justify;">The initiative is also part of Accuray’s wider strategy for accelerating technology development through a combination of internal engineering and external partnerships. La Neve said the company does not consider it necessary to develop every capability independently, particularly when collaboration can bring specialized expertise together around a specific customer or patient challenge.<o:p></o:p> <br />    <p style="text-align: justify;">The Accuray–Samsung NeuroLogica project will proceed in stages as the companies assess its technical, clinical and commercial potential. No commercial product has been announced at this stage. Any future development will remain subject to the results of the evaluation process and applicable regulatory requirements.<o:p></o:p> <br />    <p style="text-align: justify;">The collaboration adds another element to Accuray’s efforts to advance precision radiation therapy. By combining robotic radiosurgery, motion-management and precision treatment-delivery capabilities with volumetric imaging expertise, the companies are investigating whether additional anatomical information could support future radiation-treatment workflows and clinical decision-making.<o:p></o:p> <br />  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Accuray-and-Samsung-Explore-Volumetric-Imaging-for-CyberKnife_a6163.html" />
  </entry>
</feed>
